Fig. 4
From: A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies
In vitro binding affinities of Remicade, C1, C3, and C5 mAb candidates. The kinetics of the binding of the mAbs to TNF-α were determined through BLI by using human TNF-α–immobilized AR2G biosensors, followed by incubation with different concentrations of anti-TNF-α Abs. The real-time binding curves shown as color lines indicate the global fit determined using black BLItz Pro 1.2 software